Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428146 | 0.85 | HSD17B10 (0.74) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL4459257 | 0.85 | HSD17B10 (0.73) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL14740027 | 0.85 | ALDH1A1 (0.73) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL29403077 | 0.85 | ALDH1A1 (0.73) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL11739115 | 0.83 | ALDH1A1 (0.71) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL14739105 | 0.82 | LMNA (0.68) | HSD17B10KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL30093765 | 0.82 | LMNA (0.68) | HSD17B10KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL5567512 | 0.81 | KDM4E (0.68) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL7342194 | 0.79 | ALDH1A1 (0.65) | HSD17B10KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL30116222 | 0.79 | KDM4E (0.64) | HSD17B10KDM4EALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-6946462-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| EP-4340897-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340836-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230312728-A1 | Methods and Compositions for Diabetes Treatment and Beta-Cell Regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116615241-A | Methods and compositions for diabetes treatment and beta cell regeneration | 加利福尼亚大学董事会 | 2023-08-18 | — | — | CN | disclosed |
| EP-4200016-A1 | METHODS AND COMPOSITIONS FOR DIABETES TREATMENT AND BETA-CELL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | BERNARD BRUNO (FR) | 2003-03-13 | — | — | US | disclosed |
| US-6448285-B1 | DISORDERS ASSOCIATED WITH OVERACTIVITY OF 5 ALPHA REDUCTASE; ANDROGEN DEPENDENT DISORDERS SUCH AS SEBORRHOEA, ACNE, HIRSUTISM AND/OR ANDROGENIC ALOPECIA | SOCIETE L'OREAL S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| US-5563142-A | INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | THE UPJOHN COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0507861-B1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | UPJOHN CO (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5489593-A | Anti-aids piperazines | THE UPJOHN COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0507861-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. | UPJOHN CO (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
| US-4060626-A | Indole-carboxylic carbon compounds and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | HSD17B10 1110/4885KDM4E 2857/4885ALDH1A1 198/4885 |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | CYP17A1, SRD5A1, SRD5A2 | HSD17B10 20/4885KDM4E 1203/4885ALDH1A1 298/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | HSD17B10 1110/4885KDM4E 2857/4885ALDH1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.